Share-Based Payments (Tables)

6 Months Ended

Oct. 31, 2022

Share-Based Payment Arrangement [Abstract]

Summary of allocation of share based compensation expense

Stock-based compensation expense was recognized as follows (table in thousands):

	Three Months Ended October 31,				Six Months Ended October 31,
	2022		2021		2022		2021
General and administrative	$	23	$	48	$	146	$	219
Sales and marketing	49		45		97		96
Research and development	4		8		7		14
Cost of oncology services	43		33		75		85
Total stock-based compensation expense	$	119	$	134	$	325	$	414

Summary of valuation assumptions for stock options

Black-Scholes assumptions used to calculate the fair value of options granted during the six months ended October 31, 2022 and 2021 were as follows:

	Six Months Ended October 31,
	2022	2021
Expected term in years	6	6
Risk-free interest rates	2.87%	0.82%
Volatility	62.58%	65.94%-66.21%
Dividend yield	—%	—%

Summary of stock option activity

The Company’s stock options activity for the six months ended October 31, 2022 was as follows:

	Directors and Employees	Non- Employees	Total	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding, April 30, 2022	1,617,324	40,915	1,658,239	$	4.51	4.9	$	6,131,000
Granted	80,500	—	80,500	7.57		9.7
Exercised	(36,209)	—	(36,209)	3.21
Forfeited	(9,125)	—	(9,125)	7.94
Canceled	(13,374)	—	(13,374)	3.74
Expired	—	(4,584)	(4,584)	5.40
Outstanding, October 31, 2022	1,639,116	36,331	1,675,447	4.67		4.8	$	4,989,000
Vested and expected to vest as of October 31, 2022	1,639,116	36,331	1,675,447	4.67		4.8	$	4,989,000
Exercisable as of October 31, 2022	1,363,447	—	1,363,447	4.18		4.1	$	4,788,000